Platelet Aggregation Assay for Anti-CD40L Clotting Risk
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The role of the CD40/CD40L pathway in regulating coagulation at the level of platelet/endothelial cell interaction is undefined, and thromboembolic complications have been observed in clinical trials of anti-CD40L antibodies, necessitating a method to determine susceptibility to clotting upon administration.
Innovation Solution
In vitro methods involving platelet activation with agents like ADP, followed by contact with an anti-CD40L antibody and a cross-linking agent, with platelet aggregation quantified by sedimentation, to assess susceptibility to clotting, using kits that include these agents and instructions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If anti-CD40L antibody is administered to treat autoimmune disorders, then therapeutic effect is improved, but thromboembolic complications increase
Solution Approach 1:
The patent performs platelet aggregation assays before administering anti-CD40L antibody to identify patients at risk for thromboembolic complications. This preliminary screening allows clinicians to select appropriate candidates for therapy, preventing harmful effects before they occur by excluding high-risk individuals from receiving the antibody treatment.
2Reliability
If platelet aggregation is measured to assess clotting susceptibility, then patient safety is improved, but assay complexity increases
Solution Approach 1:
The assay is divided into distinct sequential steps: (1) activation of platelets with agonists, (2) addition of anti-CD40L antibody, and (3) measurement of aggregation. This segmentation into manageable stages simplifies the overall complex process, making it easier to perform and interpret while maintaining accurate safety assessment.
Solution Approach 2:
The patent uses anti-CD40L antibody as an intermediary agent in the assay to specifically probe the CD40/CD40L pathway's role in platelet aggregation. This intermediary allows selective measurement of pathway-specific aggregation mechanisms, enabling accurate risk assessment without requiring complex multi-parameter monitoring systems.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These methods allow for the determination of platelet aggregation and susceptibility to clotting, providing a basis for identifying individuals at risk of thromboembolic complications upon anti-CD40L antibody administration, enabling alternative therapeutic regimens.
Implementation Method 1
Upon activation, CD40L is translocated to the surface of platelets accompanied by surface appearance of CD63, P-selectin, and several other proteins
Implementation Method 2
contacting the activated platelets with an anti-CD40L antibody
Implementation Method 3
contacting the activated platelets with a cross-linking agent
Implementation Method 4
aggregation is quantified by sedimentation of platelets
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention provides methods of determining platelet aggregation, methods of determining susceptibility to clotting upon administration of a CD40L-binding moiety, and kits related thereto.